<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Currently listed trials (June 30, 2020) on clinicaltrial.gov with experimental anticoagulation intervention in COVID-19 infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Trial number</th>
    <th align="left">Study title</th>
    <th align="left">Location</th>
    <th align="left">Intervention</th>
    <th align="left">Primary aim</th>
    <th align="left">Target recruitment</th>
    <th align="left">Expected result date</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">NCT04445935</td>
    <td align="left">Anticoagulation in patients suffering from COVID-19 disease, The ANTI-CO Trial</td>
    <td align="left">Hamad Medical Corporation, Doha, Qatar</td>
    <td align="left">RCT of anticoagulation with bivalirudin vs. SOC heparin in patients on invasive ventilation</td>
    <td align="left">PaO2/FiO2 (P/F) ratio used as surrogate marker for oxygenation</td>
    <td align="left">100</td>
    <td align="left">March 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04362085</td>
    <td align="left">Coagulopathy of COVID 19: A pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care</td>
    <td align="left">
     <p>St Michael’s Hospital, Toronto,</p>
     <p>Canada</p>
    </td>
    <td align="left">RCT of therapeutic heparin anticoagulation vs. SOC in patients with elevated D-dimer</td>
    <td align="left">Outcome of ICU admission, invasive and non-invasive ventilation, or all-cause death up to 28 days</td>
    <td align="left">462</td>
    <td align="left">December 2020</td>
   </tr>
   <tr>
    <td align="left">NCT04406389</td>
    <td align="left">InterMediate ProphylACTic Versus Therapeutic Dose Anticoagulation in Critically Ill patients with CVID-19—A Prospective Randomized Study (The IMPACT Trial)</td>
    <td align="left">Weil Cornell Medicine, New York, USA</td>
    <td align="left">RCT of therapeutic (heparin or argatroban) vs. intermediate-dose heparin anticoagulation prophylaxis</td>
    <td align="left">30-day mortality</td>
    <td align="left">186</td>
    <td align="left">June 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04359277</td>
    <td align="left">A Randomized Trial of Anticoagulation Strategies in COVID-19</td>
    <td align="left">Langone Health, New York, USA</td>
    <td align="left">RCT of high-dose vs. low-dose enoxaparin prophylaxis in patients with elevated D-dimer</td>
    <td align="left">All-cause 1-year mortality and incidence of any thrombosis in 21 days</td>
    <td align="left">1000</td>
    <td align="left">April 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04416048</td>
    <td align="left">Effect of Anticoagulation therapy on clinical outcomes in COVID-19</td>
    <td align="left">27 centers, Germany</td>
    <td align="left">RCT of rivaroxaban vs. SOC heparin prophylaxis</td>
    <td align="left">Any thrombosis, all-cause mortality, or intubation at 35 days post randomization</td>
    <td align="left">400</td>
    <td align="left">May 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04377997</td>
    <td align="left">Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19</td>
    <td align="left">Massachusetts General Hospital, USA</td>
    <td align="left">RCT of therapeutic anticoagulation vs. SOC heparin anticoagulation</td>
    <td align="left">All-cause mortality, any thrombosis, major bleeding at 12 weeks post randomization</td>
    <td align="left">300</td>
    <td align="left">January 2022</td>
   </tr>
   <tr>
    <td align="left">NCT04367831</td>
    <td align="left">Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (IMPROVE-COVID)</td>
    <td align="left">Columbia University Medical Center, New York, USA</td>
    <td align="left">RCT of intermediate-dose vs. prophylactic dose of heparin</td>
    <td align="left">Any thrombosis within 30 days or discharge from ICU</td>
    <td align="left">100</td>
    <td align="left">April 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04345848</td>
    <td align="left">Preventing COVID-19 Complications With Low- and High-dose Anticoagulation</td>
    <td align="left">Geneva University Hospitals, Geneva, Switzerland</td>
    <td align="left">RCT of therapeutic vs. prophylactic anticoagulation with heparin</td>
    <td align="left">Any thrombosis, DIC, all-cause mortality within 30 days</td>
    <td align="left">200</td>
    <td align="left">November 2020</td>
   </tr>
   <tr>
    <td align="left">NCT04344756</td>
    <td align="left">Trial Evaluating Efficacy and Safety of Anticoagulation in patients with COVID-19 Infection, nested in the Corimmuno-19 Cohort</td>
    <td align="left">Multiple centers, France</td>
    <td align="left">RCT of therapeutic tinzaparin or unfractionated heparin with SOC heparin prophylaxis</td>
    <td align="left">Survival without ventilation at 28 days</td>
    <td align="left">808</td>
    <td align="left">September 2020</td>
   </tr>
   <tr>
    <td align="left">NCT04401293</td>
    <td align="left">Full Dose Heparin vs. Prophylactic Or Intermediate Dose Heparin in High-Risk COVID-19 Patients</td>
    <td align="left">Multiple centers, USA</td>
    <td align="left">RCT of full dose vs. prophylactic or intermediate-dose low molecular weight heparin prophylaxis</td>
    <td align="left">Any thrombosis and all-cause mortality at 30 days</td>
    <td align="left">308</td>
    <td align="left">April 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04394377</td>
    <td align="left">Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial</td>
    <td align="left">Multiple centers, Brazil</td>
    <td align="left">RCT of therapeutic anticoagulation with rivaroxaban or enoxaparin vs. prophylactic enoxaparin</td>
    <td align="left">Composite endpoint of mortality, number of days alive, stay in hospital, in oxygen, at the end of 30 days</td>
    <td align="left">600</td>
    <td align="left">December 2020</td>
   </tr>
   <tr>
    <td align="left">NCT04444700</td>
    <td align="left">A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to COVID-19 Pandemic</td>
    <td align="left">
     <p>Hospital das Clinicas da FMUSP</p>
     <p>Sao Paolo, Brazil</p>
    </td>
    <td align="left">RCT of therapeutic enoxaparin vs. SOC heparin prophylaxis in patients with low oxygen saturation</td>
    <td align="left">Composite outcome of ICU admission, invasive and non-invasive ventilation and all cause death up to 28 days</td>
    <td align="left">462</td>
    <td align="left">December 2020</td>
   </tr>
   <tr>
    <td align="left">NCT04360824</td>
    <td align="left">Covid-19-Associated Coagulopathy</td>
    <td align="left">University of Iowa, USA</td>
    <td align="left">RCT of standard-dose vs. intermediate-dose enoxaparin prophylaxis</td>
    <td align="left">All-cause mortality at 30 days</td>
    <td align="left">170</td>
    <td align="left">April 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04354155</td>
    <td align="left">COVID-19 Anticoagulation in Children—Thromboprophylaxis (COVAC-TP) Trial</td>
    <td align="left">Johns Hopkins All Children's Hospital, Saint Petersburg, FL, USA</td>
    <td align="left">Single group assignment of twice-daily enoxaparin prophylaxis</td>
    <td align="left">Safety of enoxaparin, fatal bleeding, any major bleeding within 30 days</td>
    <td align="left">38</td>
    <td align="left">October 2022</td>
   </tr>
   <tr>
    <td align="left">NCT04409834</td>
    <td align="left">Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial</td>
    <td align="left">TIMI Study group, USA</td>
    <td align="left">RCT of full dose or prophylactic dose heparin with or without clopidogrel</td>
    <td align="left">Any thrombosis at 28 days post randomization</td>
    <td align="left">750</td>
    <td align="left">May 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04372589</td>
    <td align="left">Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)</td>
    <td align="left">Multiple centers, USA</td>
    <td align="left">RCT of therapeutic dose vs. prophylactic dose heparin anticoagulation</td>
    <td align="left">Ordinal endpoint of no ventilation or invasive ventilation or death</td>
    <td align="left">3000</td>
    <td align="left">January 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04412304</td>
    <td align="left">Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients</td>
    <td align="left">South General Hospital, Stockholm, Stockholms Län, Sweden</td>
    <td align="left">Retrospective observational study of conventional, double dose, and therapeutic anticoagulation with tinzaparin or dalteparin</td>
    <td align="left">ICU mortality at 28 days</td>
    <td align="left">166</td>
    <td align="left">May 2020</td>
   </tr>
   <tr>
    <td align="left">NCT04333407</td>
    <td align="left">Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial</td>
    <td align="left">Charing Cross Hospital, London, UK</td>
    <td align="left">RCT of aspirin or clopidogrel or rivaroxaban with atorvastatin and omeprazole</td>
    <td align="left">All-cause mortality at 30 days after admission</td>
    <td align="left">3170</td>
    <td align="left">March 2021</td>
   </tr>
   <tr>
    <td align="left">NCT04366921</td>
    <td align="left">European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO</td>
    <td align="left">Multiple (97) centers in Europe, Russia, and Israel</td>
    <td align="left">Observational study in ECMO patients</td>
    <td align="left">Clinical outcome at 6 months</td>
    <td align="left">150</td>
    <td align="left">April 2021</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>DIC</italic> disseminated intravascular coagulation, 
   <italic>ECMO</italic> extracorporeal membrane oxygenation, 
   <italic>ICU</italic> intensive care unit, 
   <italic>RCT</italic> randomised controlled trial, 
   <italic>SOC</italic> standard of care, 
   <italic>TIMI</italic> thrombolysis and myocardial infarction
  </p>
 </table-wrap-foot>
</table-wrap>
